Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Completed1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed133%
withdrawn133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

NCT04555811
terminatedphase_1

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

NCT04245722
withdrawnphase_1

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

NCT05934097

Clinical Trials (3)

Showing 3 of 3 trials
NCT04555811Phase 1

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Completed
NCT04245722Phase 1

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Terminated
NCT05934097Phase 1

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3